Press Room

Event

2023 AIChE Annual meeting

Start
Sunday, November 05, 2023 - 09:00
End
Friday, November 10, 2023 - 17:00
Location: Orlando, United States
AIChE 2023 Annual Meeting | Hovione

Meet Hovione team at the 2023 AIChE Annual Meeting and find their exciting presentations and Hovione’s latest research and innovations. The AIChE Annual Meeting is an educational forum covering a wide range of topics relevant to cutting-edge research, new technologies, and emerging growth areas in chemical engineering. We look forward to meeting academic and industry experts and exchanging knowledge.

 



Date: November 5, 2023

Oral Presentation 547b

Title: PAT Development Strategy in the Feed Frame As an Enabler for Faster Continuous Manufacturing Implementation

Presenting Author: Pedro Durão (Senior Scientist II, Modelling & PAT)

3:51 PM - 4:12 PM

Celebration 7 (Convention Level)

Oral Presentation 653f

Title: Modeling Continuous Film Coating Process in Consigma Coater: What Changes?

Presenting Author: Pedro Monteiro (Scientist, Formulation Development)

5:15 PM - 5:36 PM

Celebration 8 (Convention Level)

Oral Presentation 653g

Title: Model-Based Application for a Safe Scale-up and Equipment Selection on a Pressure Generating Pharmaceutical Process

Presenting Author: Frederico Montes (Scientist, Corporate Technical Services)

5:36 PM - 5:57 PM

Celebration 8 (Convention Level)



 

Date: November 6, 2023

Session 113 - Particle Characterization

Chair: Sarang Oka, Continuous Manufacturing Development Engineer

12:30 PM - 3:00 PM

Bayhill 19 (Lobby Level)

Poster Presentation 198d

Title: Development and Application of Residence Time Distribution (RTD) Models for a Continuous Direct Compression Process

Presenting Author: José Granjo (Modelling & PAT Scientist)

3:30 PM - 5:00 PM

Regency Ballroom R/S (Convention Level) 

Poster Presentation 198v

Title: Cryo Jet Milling for Micronization Enhancement of Inhalation Particles

Presenting Author: Inês Gomes (IST), with João Pires, Filipe Vultos, Ricardo Velez (Scientists, Hovione) and Ana Azevedo (IST)

3:30 PM - 5:00 PM

Regency Ballroom R/S (Convention Level)

Poster Presentation 643g

Title: A Template for Investigating NIR Spectroscopy-Based Deviations

Presenting Author: Ankita Naik (Modelling & PAT Scientist, CM Process Development)

5:36 PM - 5:57 PM

Celebration 8 (Convention Level)



 

Date: November 7, 2023

Oral Presentation 500g

Title: Recent Advances in ASD Formulations: Combining Dispersome® Technology with a High-Throughput Screening Setup

Presenting Author: Inês Ramos (Senior Scientist, Formulation Development)

1:08 PM - 1:26 PM

Manatee Spring II (Lobby Level)

Oral Presentation 500h

Title: Amorphous Solid Dispersions By Spray Drying: From Early Formulation to Commercial Lifecycle Management

Presenting Author: José Luís Santos, Director, Technology Intensification

1:26 PM - 1:44 PM

Manatee Spring II (Lobby Level)

Oral Presentation 583a 

Title: Impact of Rheology and Process Variables on the Development and Scale-up of a Drum Filling Process for Dry Powder Inhalers

Presenting Author: Rui Churro (Senior Scientist, Process Development)

3:30 PM - 3:51 PM

Celebration 8 (Convention Level)

Oral Presentation 583d

Title: Droplet to Particle model prediction by coupling solution rheological characterization, CFD and Phase doppler analysis

Presenting Author: Márcia Tavares (Scientist, Process Development)

4:33 PM - 4:54 PM

Celebration 8 (Convention Level)



 

Date: November 8, 2023

Oral Presentation 74c

Title: Bridging Crystallization and Mechanical Properties to Particle Size Reduction Efficiency in Jet Milling Industrial Pharmaceutical Processes

Presenting Author: Gonçalo Marcelo (Scientist, Particle Engineering)

9:00 AM - 9:20 AM

Bayhill 19 (Lobby Level) 

Poster Presentation 303r

Title: Integrating Three-Fluid Nozzle Technology as a QbD Tool for Enhancing Advanced Respiratory Drug Delivery Formulations: A Statistical Modeling Approach 

Presenting Author: Rui Churro (Senior Scientist, Process Development)

3:30 PM - 5:00 PM

Regency Ballroom R/S (Convention Level)

Poster Presentation 84at

Title: Asset Intensification: Application of Modelling Tools and Methodologies from a CDMO Perspective

Presenting Author: Filipe Ataide (Senior Scientist, Technology Intensification)

3:30 PM - 5:00 PM

Regency Ballroom R/S (Convention Level)

 

 

Date: November 9, 2023

Oral Presentation 355e

Title: Controlled Crystallization through Microfluidization As an Alternative Particle Engineering Technology for Inhalation Products

Presenting Author: Gonçalo Marcelo (Scientist, Particle Engineering)

9:24 AM - 9:45 AM

Celebration 8 (Convention Level)

Oral Presentation 649e

Title: Use of Statistical Process Control to Drive Process Improvements in Continuous Manufacturing

Presenting Author: Ankita Naik (Modelling & PAT Scientist, CM Process Development)

4:58 PM - 5:20 PM

Celebration 8 (Convention Level)

 

 

 

schedule a meeting
https://www.hovione.com/contact-us

 

 

 

Schedule your meeting today 

 

 

Also in the Press Room

See All

Key Takeaways Commissioning a US-based ConsiGma CDC Flex line enables end-to-end spray drying-to-tablet manufacture within a single site and quality system, reducing comparability and technology-transfer burdens. Elimination of conventional scale-up is enabled by using the same equipment from early development through commercial supply, minimizing engineering runs and conserving scarce API. Operational flexibility spans batch or continuous modes and 1–200 kg/h throughput, with scale adjustment achieved by switching continuous blenders rather than replatforming processes. High-containment design to 1 µg/m³ expands suitability for highly potent oral solid-dose programs while maintaining integrated development-to-commercial workflows. Regulatory momentum for continuous manufacturing is supported by ICH Q13 harmonization, increasing FDA approvals, and platforms leveraging inline PAT and automated control suites for real-time quality assurance. Hovione announced on Oct. 5, 2026, that it will commission the ConsiGma CDC Flex, a next-generation continuous direct compression tableting platform jointly developed with GEA. The investment is designed to link amorphous solid dispersion manufacturing via spray drying with commercial tablet production at a single US site operating under one quality system. The line will run in either continuous or batch mode at throughputs from 1 to 200 kg/h. Formulation development can begin with as little as 1.5 kg of material, and the same equipment can then support everything from very small clinical batches to large commercial runs, enabled by a design that allows the system to switch between continuous blenders of different sizes. The installation will also be contained to 1 µg/m³ to accommodate highly potent compounds. "Hovione will be the first company in the world to offer the ConsiGma® CDC Flex, bringing this next-generation technology with unprecedented flexibility, simplicity and cost-efficiency in continuous tableting," said Marco Gil and António Almeida, co-CEOs, Hovione, said in a press release. "This investment also advances our strategy of building integrated capabilities close to customers in key markets. By adding this new line at East Windsor, we are broadening access to this technology in the U.S. and giving customers a more direct and accelerated path for developing and commercializing complex oral medicines." What Does a Single Development-To-Commercial Line Change? For formulators and process engineers, the most consequential claim is the removal of traditional scale-up. Moving a process from development equipment to commercial equipment typically requires engineering runs, bridging work, and consumption of scarce API, all of which weigh heavily on early programs with limited material. "Installing the CDC Flex at 89 Twin Rivers makes continuous tableting part of an integrated US development and manufacturing workflow," said David Basile, Vice President of Technical Operations, Hovione, in the press release. "Customers can move from formulation and particle engineering to commercial tablets with one Hovione team and one quality system, eliminating traditional scale-up while gaining greater production flexibility, process control and supply continuity." Co-locating spray drying and tableting is also significant because amorphous solid dispersions remain a primary solubility-enhancement route for poorly soluble molecules, and transferring intermediates between sites or vendors adds technology transfer and comparability burdens. The new line builds on the company's earlier US expansion; Hovione recently completed a $100 million investment to bolster US capacity in particle design, amorphous solid dispersions via spray drying, and batch and continuous tableting. How Is the Regulatory Environment Shaping Continuous Tableting Adoption? The company points to the 2022 adoption of ICH Q13, which provides harmonized guidance for continuous manufacturing of drug substances and drug products across the US, Europe, and Japan. Hovione reports that, as of 2024, FDA alone had approved 17 products manufactured under the guidance. Speaking on ICH Q13, FDA's Kelley Burridge, PhD, "Perceived barriers to continuous manufacturing have been falling one by one," and noted an FDA publication showing faster approval times for products with continuous manufacturing elements than for comparable batch products. The platform incorporates inline process analytical technology and automated controls for real-time quality monitoring, along with SimpleCT, an automation and control suite intended to support a single process from development through commercial supply. For sponsors weighing supply resilience and regional sourcing, the East Windsor installation extends a capability that Hovione says only it currently offers as a contract development and manufacturing organization.   Read the full article at PharmTech.com  

Press Clipping
PharmTech, 5 October 2026

Can Continuous Tableting End Scale-Up for Complex Oral Drugs?

Oct 05, 2026

Formulation Development/Drug Product Manufacturing  Hovione Completes $46-M Tablet Mfg Facility Expansion  Hovione, a CDMO of drug substances and drug products, has completed an expansion of its tablet development and manufacturing center at its main global campus in Loures, Portugal, adding 25% more commercial-scale batch tableting capacity for oral solid dosage products. The expansion strengthens integrated manufacture of amorphous solid dispersions by spray drying and tableting at a single site. The recently inaugurated expansion completes an investment cycle of more than EUR 40 million ($46 million).  Hovione expanded its batch tableting capacity by adding an additional line mirroring the original unit across every local operation: dispensing, blending, dry granulation, tableting, and film coating. The mirrored configuration reinforces capacity at the 300 kg to 400 kg batch scale and provides both redundancy and like-for-like product transfers between lines. Supporting areas, including in-process control and staging space sized to the increased production capacity, were also added as part of the expansion.  Read the full article at DCATVCI.org  

Press Clipping
DCAT Value Chain Insights, 3 September 2026

Supplier News: Lonza, Evonik, Hovione, Catalent & More

Sep 03, 2026

The company is building out more than 200,000 square feet of space in New Jersey. In April, Contract Pharma had the opportunity to tour Hovione’s expanded manufacturing facility in East Windsor, NJ. The company is planning a formal ribbon-cutting this fall; before that, we got an inside look at some new features. Having established United States operations in 2002, Hovione now has more than 200,000 square feet of space in New Jersey. This will be developed into a large, integrated campus in the next five to ten years. Overall, the company’s recent NJ expansion, which began in 2025, has tripled its total spray-drying capacity in the U.S. Future Facility Upgrades A 125,000-square-foot greenfield acquired by Hovione at the East Windsor campus will eventually be a large-scale production site. This includes enhanced quality control and R&D capabilities. Together, all this adds to Hovione’s stable of manufacturing sites, R&D centers, and other offices spread across three continents. Key to the expansion is a targeted reduction of Hovione’s carbon footprint by 40% by the year 2030. Part of this goal is embracing new and/or changing solvent types to help meet sustainability standards. Additionally, the company says automation that has been put in place at its Portugal site will be replicated in NJ. Hovione Aligns NJ Operations At the Drug, Chemical & Associated Technologies Association (DCAT) Week in New York in March, Contract Pharma met with Hovione. There, David Basile, Vice President of Technical Operations—Americas, further illustrated the New Jersey expansion. “Hovione aims to build an equivalent manufacturing network, where clients can go to any site across the globe,” Basile said. “The design of the facility has been well-thought through with material flows [and] gravity-fed processes. It’s scalable. We call each one of these building segments a finger. You can copy and paste these fingers, and they are built to house both spray drying and drug product assets.” Ultimately, with these moves and a strategic partnership model, Hovione aims to provide customers an opportunity to co-invest and access the company’s proprietary knowledge and assets to accelerate programs and create long-term value. Read the full article at ContractPharma.com    

Press Clipping
Contract Pharma, 31 July 2026

Hovione Planning Ribbon-Cutting at NJ Facility – A Behind-the-Scenes Preview

Jul 31, 2026

Also in Events

See All